16-18 July 2018 | Boston


Day One
Tuesday, July 17th 2018

Day Two
Wednesday, July 18th 2018

Advancing Preclinical Modeling to Enhance the Translational Success of Anti-Cancer Therapies

Developing Checkpoint Target Humanized Models for Pre-clinical Efficacy Assessment

Pre-clinical Modeling of Immune Responses to Cancer: From Bench- Side to Clinical Outcomes

Patient-Derived Tumor Xenografts in Humanized NSG-SGM3 Mice: A New Immuno-Oncology Platform

  • Rick Huntress Director - Business Development, Clinical & In Vivo Services Business Development, Clinical & In Vivo Service, The Jackson Laboratory

Speed Networking and Morning Refreshments

Modelling Sensitivity and Resistance, and Examining Strategies to Overcome Them

11.00 Myeloid Derived Suppressor Cells In Tumor Microenvironment

Dmitry Gabrilovich, Professor & Program Leader – Translational Tumor Immunology Program, The Wistar Institute

11.30 Targeting Cellular Plasticity to Overcome Resistance

John M. Ruppert, Professor of Biochemistry & Jo and Ben Statler Chair of Breast Cancer Research; West Virginia University School of Medicine

12.00 Spotlight Presentation: Syngeneic Models of Breast and Ovarian Cancers: Effects of Immune Modulatory Agents in Classically “Cold” Tumors

Maryland Franklin, Vice President – Scientific Development, MI Bioresearch

Leveraging the TME in Anti-Cancer Therapies

11.00 Understanding the Role of Stromal Cells in the Tumor Microenvironment and the Effect of Cross-Talk with Immune Cells

Zhao Chen, Investigator III, Genomics Institute of the Novartis Research Foundation (GNF)

11.30 The Roles of Tumor Microenvironment on Efficacy and Pharmacokinetics of Antibody-Drug Conjugates

Fu Li, Principal Scientist, Immunology, Seattle Genetics

12.00 Spotlight Presentation: Influence of Microenvironment in Primary & Bone Tumor Breast Cancer Models

Jenni Bernoulli, Chief Operating Officer, Pharmatest Services

Lunch & Networking

TME Metabolism: A New Checkpoint for Anti-Tumor Immunity

13.15 Exploring Interconnected Pathways Regulating the TME and Tumorigenesis Through Gene Profiling and Epigenetic Analysis

William Muller, Professor, Biochemistry, McGill University

13.45 Translating Preclinical Hypotheses of Tumor Sensitivity to EZH2 Inhibition in NHL to Clinical Proof of Concept

Neil Michaud, Associate Director – Translational Medicine, EpiZyme

14.15 Spotlight Presentation: Ultrasound Imaging of Patient Avatars Demonstrates Intratumoral Heterogeneous Response to Systemic Therapy and Immunotherapy

Matthew Lowerison, Postdoctoral Fellow, Mayo Clinic

Biomarker Development

13.15 Evaluating the Predictability of Preclinical Models Through Correlation Analysis of Clinical Data for Targeted Therapies

Christopher L. Murriel, Associate Director, Research, OncoMed Pharmaceuticals, Inc.

13.45 Integrated Analyses of Environmental, Microbial, Tumor, and Immune Factors for Precision Immuno- Oncology

Shuji Ogino, Professor and Chief of Program in MPE Molecular Pathological Epidemiology at Brigham and Women’s Hospital

14.15 Spotlight Presentation: Circulating Tumor Cell (CTC) Analysis in Pre-Clinical Models of Cancer Metastas

Speaker to be confirmed, Angle Plc

Afternoon Refreshments & Networking

Designing Next Generation Immuno-therapies

Strategies for Using Models in Engineered T Cell Research and Development

Highlighting Clinical Outcomes of CAR-T Therapies to Enhance Translational Insights from Preclinical Models

  • David Teachey Associate Professor of Paediatrics, Divisions of Haematology and Oncology, Children’s Hospital of Philadelphia

Chairs Closing Remarks

Close of Day One

Hosted By Crown Bioscience: Evening Drinks Reception & Scientific Poster Session


After the formal presentations have finished, the learning and networking carries on.

No more sitting quietly, the Poster Session is an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships.

During this session scientific posters will be presented on models validating innovative targets, disease models highlighting novel mechanisms and platforms enabling effective prediction of clinical efficacy.